Previous close | 8.90 |
Open | 8.90 |
Bid | 8.50 |
Ask | 9.60 |
Strike | 25.00 |
Expiry date | 2026-01-16 |
Day's range | 8.90 - 8.90 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.